|
163 Companies |
|
218 Products |
|
218 Products |
|
112 Mechanisms of Action |
|
6 Trials |
|
2483 News |
|
| 12345678910111213...5051» |
- | opigolix (ASP1707) / Astellas
Phase classification: A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate (clinicaltrials.gov) - Oct 23, 2024
P2, N=72, Completed, Sponsor: Astellas Pharma Inc
Phase classification: P2a --> P2
- | NN1213 / Novo Nordisk
Trial termination: Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 18, 2024
P=N/A, N=400, Terminated, Sponsor: University of Birmingham
Phase classification: P2a --> P2 Active, not recruiting --> Terminated; Incomplete student research project
- ||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Enrollment change, Trial termination: An Observational Study to Evaluate Safety and Efficacy of Remsima (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=248, Terminated, Sponsor: Celltrion
Active, not recruiting --> Terminated; Incomplete student research project N=950 --> 248 | Recruiting --> Terminated; Terminated
- | fosdagrocorat (PF-04171327) / Pfizer
Phase classification: A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis (clinicaltrials.gov) - Nov 22, 2023
P2, N=86, Completed, Sponsor: Pfizer
N=950 --> 248 | Recruiting --> Terminated; Terminated Phase classification: P2a --> P2
- | leflunomide / Generic mfg.
Enrollment change, Head-to-Head: Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood (clinicaltrials.gov) - Sep 8, 2023
P=N/A, N=10, Completed, Sponsor: Chinese Academy of Sciences
Phase classification: P2a --> P2 N=15 --> 10
- ||| Trial completion: PRISM: Pictorial Representation of Illness and Self Measure (clinicaltrials.gov) - Apr 30, 2019
P=N/A, N=220, Completed, Sponsor: University of Oxford
N=15 --> 10 Active, not recruiting --> Completed
- ||| NN1213 / Novo Nordisk
Trial completion: Implantology and Sj (clinicaltrials.gov) - Apr 30, 2019
P=N/A, N=120, Completed, Sponsor: Derk Jan Jager
Active, not recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: REMINDRA: REMission INDuction in Very Early Rheumatoid Arthritis (clinicaltrials.gov) - Apr 29, 2019
P4, N=53, Terminated, Sponsor: UMC Utrecht
Recruiting --> Completed N=267 --> 53 | Trial completion date: Nov 2023 --> Jan 2019 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jan 2019; low recruitment rate
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Discordant: DIAPO: Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity (clinicaltrials.gov) - Apr 25, 2019
P=N/A, N=200, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
N=267 --> 53 | Trial completion date: Nov 2023 --> Jan 2019 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jan 2019; low recruitment rate Active, not recruiting --> Completed | N=79 --> 200
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of Flt3-Ligand Levels in Sj (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=30, Completed, Sponsor: G
Active, not recruiting --> Completed | N=79 --> 200 Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019
- Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=67, Terminated, Sponsor: Zimmer Biomet
Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019 N=120 --> 67 | Trial completion date: Dec 2024 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Dec 2018; Business decision was made to remove the CE mark from this product, thus prompting the closing of this study.
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Resistance Exercise in Rheumatic Disease (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=15, Terminated, Sponsor: Johns Hopkins University
N=120 --> 67 | Trial completion date: Dec 2024 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Dec 2018; Business decision was made to remove the CE mark from this product, thus prompting the closing of this study. N=10 --> 15 | Trial completion date: Jun 2019 --> Dec 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Dec 2018; Funding ended.
- | NN1213 / Novo Nordisk
Biomarker, Trial completion: Salivary Biomarkers for Sj (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=420, Completed, Sponsor: University of California, Los Angeles
N=10 --> 15 | Trial completion date: Jun 2019 --> Dec 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Dec 2018; Funding ended. Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PRESSRA: The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=23, Terminated, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=50 --> 23 | Trial completion date: Dec 2018 --> Jul 2018 | Suspended --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Funding ended
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound (clinicaltrials.gov) - Apr 17, 2019
P=N/A, N=16, Completed, Sponsor: University of Southern California
N=50 --> 23 | Trial completion date: Dec 2018 --> Jul 2018 | Suspended --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Funding ended Recruiting --> Completed | N=25 --> 16
- ||||| Tai'ai (telitacicept) / Rongchang Pharma
Trial completion date, Trial termination, Trial primary completion date: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-? Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis (clinicaltrials.gov) - Apr 3, 2019
P2, N=60, Terminated, Sponsor: RemeGen
Recruiting --> Completed | N=25 --> 16 Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2019; Lack of trial population, unable to recruit subjects
- ||| NN1213 / Novo Nordisk
Trial completion: G7 Acetabular System vs. Exceed ABT Acetabular System in THA (clinicaltrials.gov) - Mar 26, 2019
P=N/A, N=160, Completed, Sponsor: Zimmer Biomet
Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2019; Lack of trial population, unable to recruit subjects Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: SPIRALE: Study During Pregnancy of Expression of miRNAs in RA or SLE (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=50, Completed, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jul 2019 --> Oct 2018 | Trial primary completion date: Jul 2019 --> Oct 2018
- | zoledronic acid / Generic mfg.
Enrollment change, Trial completion date, Trial termination: AZAR: Zoledronic Acid in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2019
P3, N=28, Terminated, Sponsor: Carmen G
Recruiting --> Completed | Trial completion date: Jul 2019 --> Oct 2018 | Trial primary completion date: Jul 2019 --> Oct 2018 N=94 --> 28 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated
- ||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Combination therapy, Monotherapy: EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2019
P=N/A, N=200, Completed, Sponsor: Hoffmann-La Roche
N=94 --> 28 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated Active, not recruiting --> Completed
- ||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: APRAN: Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=80, Completed, Sponsor: Isabelle Fortin
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Sep 2019 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Nov 2018
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: BIOSAFE: Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=129, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial completion date: Sep 2019 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Nov 2018 Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2018 --> Nov 2018
- || Orencia (abatacept) / BMS
Trial completion date, Trial primary completion date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) (clinicaltrials.gov) - Jan 18, 2019
P=N/A, N=20000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2018 --> Nov 2018 Trial completion date: Oct 2019 --> Jun 2029 | Trial primary completion date: Oct 2019 --> Jun 2029
- | NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Discordant: DIAPO: Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=79, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Trial completion date: Oct 2019 --> Jun 2029 | Trial primary completion date: Oct 2019 --> Jun 2029 Recruiting --> Active, not recruiting | N=200 --> 79 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- | Trial completion, Trial completion date: Douleur-PR: Pain Evaluation in Rheumatoid Arthritis (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=300, Completed, Sponsor: University Hospital, Limoges
Recruiting --> Active, not recruiting | N=200 --> 79 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Sep 2015 --> Dec 2017
- | NN1213 / Novo Nordisk
Trial completion: NeuroSenSS: Primary Sj (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=44, Completed, Sponsor: University Hospital, Limoges
Active, not recruiting --> Completed | Trial completion date: Sep 2015 --> Dec 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date: Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=13, Completed, Sponsor: University of British Columbia
Recruiting --> Completed Active, not recruiting --> Completed | N=20 --> 13 | Trial completion date: Jun 2019 --> Jan 2018
- ||| Remicade (infliximab) / J&J
Trial completion: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=140, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
Active, not recruiting --> Completed | N=20 --> 13 | Trial completion date: Jun 2019 --> Jan 2018 Active, not recruiting --> Completed
- | Enrollment change, Trial withdrawal: Gender Solutions Natural Knee Post-Market Study (clinicaltrials.gov) - Jan 9, 2019
P=N/A, N=0, Withdrawn, Sponsor: Zimmer Biomet
Active, not recruiting --> Completed N=300 --> 0 | Suspended --> Withdrawn
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Tocihelper: Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation (clinicaltrials.gov) - Jan 9, 2019
P=N/A, N=60, Completed, Sponsor: Association Aquitaine de Recherche Clinique en Rhumatologie
N=300 --> 0 | Suspended --> Withdrawn Recruiting --> Completed
- ||| Trial completion, Phase classification, Enrollment change: Total Knee Arthroplasty (TKA) Cemented Versus Cementless Tibial Prosthesis Study (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=106, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=250 --> 106
- | Trial completion date, Trial primary completion date: Resistance Exercise in Rheumatic Disease (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=10, Suspended, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=250 --> 106 Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Kineret (anakinra) / SOBI
Enrollment change, Trial termination, Trial primary completion date: TRACK: Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes (clinicaltrials.gov) - Dec 14, 2018
P4, N=41, Terminated, Sponsor: Prof. Roberto Giacomelli
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 N=200 --> 41 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Dec 2017; Decision of the Sponsor for Early Benefits
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial completion date, Trial primary completion date: Niclosamide With Etanercept in Rheumatoid Arthritis (clinicaltrials.gov) - Dec 12, 2018
P1/2, N=110, Completed, Sponsor: Faiq Gorial
N=200 --> 41 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Dec 2017; Decision of the Sponsor for Early Benefits Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018
- || tibulizumab (ZB-106) / Zura Bio
Trial completion: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Dec 11, 2018
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018 Active, not recruiting --> Completed
- Kinaction (masitinib) / AB Science
Trial completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 10, 2018
P2b, N=324, Terminated, Sponsor: AB Science
Active, not recruiting --> Completed Trial completion date: Jun 2018 --> Sep 2016
- || Kinaction (masitinib) / AB Science
Trial completion, Combination therapy: Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2018
P2, N=20, Completed, Sponsor: AB Science
Trial completion date: Jun 2018 --> Sep 2016 Active, not recruiting --> Completed
- Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2018
P2b, N=324, Terminated, Sponsor: AB Science
Active, not recruiting --> Completed Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018
- ||| Trial completion, Phase classification, Enrollment change: Augment (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=299, Completed, Sponsor: BioMimetic Therapeutics
Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018 Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=201 --> 299
- | fosdagrocorat (PF-04171327) / Pfizer
Phase classification: A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis (clinicaltrials.gov) - Dec 4, 2018
P2a, N=86, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=201 --> 299 Phase classification: P2 --> P2a
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ESPERA: Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis (clinicaltrials.gov) - Dec 3, 2018
P=N/A, N=22, Completed, Sponsor: University Hospital, Toulouse
Phase classification: P2 --> P2a Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Nov 30, 2018
P=N/A, N=30, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016 Active, not recruiting --> Completed
- | Humira (adalimumab) / AbbVie
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy: Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate (clinicaltrials.gov) - Nov 26, 2018
P=N/A, N=0, Withdrawn, Sponsor: AbbVie
Active, not recruiting --> Completed N=60 --> 0 | Trial completion date: Oct 2019 --> Nov 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2019 --> Nov 2018
- | Enrollment change: PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) - Nov 21, 2018
P=N/A, N=231, Completed, Sponsor: Corin
N=60 --> 0 | Trial completion date: Oct 2019 --> Nov 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2019 --> Nov 2018 N=350 --> 231
- | Trial completion, Enrollment change, Trial initiation date: Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis (clinicaltrials.gov) - Nov 20, 2018
P=N/A, N=70, Completed, Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
N=350 --> 231 Active, not recruiting --> Completed | N=168 --> 70 | Initiation date: Jun 2016 --> Apr 2012
- | Trial completion, Trial completion date, Trial primary completion date: PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) - Nov 19, 2018
P=N/A, N=350, Completed, Sponsor: Corin
Active, not recruiting --> Completed | N=168 --> 70 | Initiation date: Jun 2016 --> Apr 2012 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Jun 2017
- | NN1213 / Novo Nordisk
Enrollment closed: A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis (clinicaltrials.gov) - Nov 14, 2018
P1, N=12, Active, not recruiting, Sponsor: Arthrogen
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Jun 2017 Recruiting --> Active, not recruiting
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab (clinicaltrials.gov) - Nov 14, 2018
P=N/A, N=35, Completed, Sponsor: Fundaci
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Oct 2018
- | Remicade (infliximab) / J&J
Trial completion date, Trial primary completion date: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Nov 2, 2018
P=N/A, N=140, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Oct 2018 Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018
- | Biomarker, Trial completion: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (clinicaltrials.gov) - Oct 31, 2018
P4, N=115, Completed, Sponsor: Medical University of Vienna
Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018 Active, not recruiting --> Completed